1. 1. Atarashi H, Sasaki H, Ohsaka M, Sasaki Y, Hayakawa H, Tomono Y, Morishita N. A phase I study of E-1020 — intravenous injection. Jpn J Clin Pharmacol Ther, 21: 613-621, 1990.
2. 2. Kimata S, Hirosawa K, Kasanuki H, Takano T, Serizawa T, Sasayama S, Kumada T, Hori S, Hiramori K. Clinical effects of olprinone on acute heart failure : evaluation of acute hemodynamic effects of bolus injection and continuous infusion. Rinshyoo To Kenkyuu (Jpn J Clin Exp Med), 69: 2260-2274, 1992.
3. 3. Takaoka H, Takeuchi M, Odake M, Hayashi Y, Mori M, Hata K, Yokoyama M. Comparison of the effects on arterial-ventricular coupling between phosphodiesterase inhibitor and dobutamine in the diseased human heart. J Am Coll Cardiol, 22: 598-606, 1993.
4. 4. Sha K, Iwata M, Mori M, Motozu Y, Yonemoto N, Kitaguchi K, Hirai K, Furuya H. Evaluation of the different doses of olprinone for continuous infusion after cardiopulmonary bypass for coronary artery bypass surgery. Masui (Jpn J Anesthesiol), 52: 621-625, 2003.
5. 5. Ogawa T, Ohhara H, T sunoda H, Kuroki J, Shoji T. Cardiovascular effects of the new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridine-6-y1)-3-pyridine carbonitrile hydrochloride monohydrate. 1st communication: studies on isolated guinea pig cardiac muscles. Arzneim Forsch Drug Res, 39: 33-37, 1989.